You are here: Industry Insights > SII

News List

1600 participants enrolled for Phase III clinical trials of Covishield expresspharma
November 12, 2020
SII and ICMR are conducting Phase 2/3 clinical trial of COVISHIELD at 15 different centres, across the country.
SII pauses trials of COVID-19 vaccine candidate Covishield in India expresspharma
September 23, 2020
The company took this step after the DCGI issued a show cause notice to the company for not informing it about AstraZeneca pausing the clinical trials of the vaccine candidate in other countries.
DCGI issues notice to Serum Institute over AstraZeneca-Oxford COVID-19 vaccine trial suspension expresspharma
September 18, 2020
If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocol, said SII in response to show cause notice.
Beximco signs deal with Serum Institute of India for COVID-19 vaccines expresspharma
August 31, 2020
Beximco Pharmaceuticals from Bangladesh announced investment in the Serum Institute of India (SII) for priority access to COVID-19 vaccines being developed by the Indian pharma manufacturer.
SII, Gavi and BMGF collaborate for COVID-19 vaccines, SII to price per vaccine dose at Rs 225 expresspharma
August 10, 2020
Serum Institute of India to produce up to 100 million COVID-19 vaccine doses which will be made available to the 92 countries included in Gavi’s COVAX Advance Market Commitment.
COVID-19 panel recommends DCGI to permit SII to conduct human trials of Oxford vaccine candidate expresspharma
August 03, 2020
SII had submitted a revised proposal on Wednesday after the expert panel had asked it to revise its protocol for the trials besides seeking some additional information.
DCGI asks SII to revise protocol for phase 2, 3 trials of Oxford COVID-19 vaccine expresspharma
July 30, 2020
SII has submitted a revised protocol for conducting the trials to the DCGI.
SII enrols 6000 subjects for efficacy trial of rBCG vaccine, VPM1002 against COVID-19 expresspharma
July 28, 2020
The DBT-BIRAC supported trial aims to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons of advanced age or co-morbidities and high-exposure healthcare workers.
Serum Institute of India expects COVID vaccine by year-end expresspharma
July 09, 2020
He was speaking during the launch of 'Compact XL, a compact diagnostics machine by MyLab Discovery Solutions, that will automate lab processes from sample handling to preparing RT-PCR tubes.

Previous page 1 2 3 4 5 6 Next page